IDFC First Bank declined 4.78% to Rs 62.40 after the bank’s standalone net profit declined 97.33% to Rs 20.06 crore despite 21.61% jump in total income to Rs 10,684.23 crore in Q2 FY25 over Q2 FY24.
Stock market update: Nifty Bank index 1.48% in an upbeat market (28-10-2024)
The Nifty Bank index was trading 1.48 per cent at 51538.60.
Colgate-Palmolive shares 0.92 per cent in Monday’s trading session (28-10-2024)
The Relative Strength Index of the stock stood at 23.27 on Monday.
Time Technoplast gains as board OKs raising Rs 1,000-cr via QIP (28-10-2024)
Time Technoplast added 2.33% to Rs 407.95 after its board approved raising of funds through qualified institutions placement (QIP) for upto Rs 1,000 crore and/or any other permissible mode.
Spicejet launches New Flights for winter schedule (28-10-2024)
Expands Domestic and International connectivity
Indus Towers Limited (28-10-2024)
hmm…gt it…
any views on the results, if you have been tracking it fundamentally?
Sensex rises! These stocks are up over 15% on BSE (28-10-2024)
In the Nifty50 index, 41 stocks were trading in the green, while 9 stocks were in the red.
Yes Bank spurts as PAT zooms to Rs 553 crore in Q2 FY25 (28-10-2024)
Yes Bank surged 8.14% to Rs 20.98 after the private bank’s standalone net profit zoomed 145.56% to Rs 553.04 crore on 15.35% rise in total income to Rs 9,137.09 crore in Q2 FY25 over Q2 FY24.
Sudarshan Chemicals – Can it colour our portfolio green? (28-10-2024)
More than 70% of the acquisitions fail. With that as the base rate, the acquisition of Heubach is going to be challenging for Sudarshan. Added to it, the acquisition is going to be funded partly with debt. And more money will be required to be infused into operations of Heubach. All this will add to the challenges and leverage of Sudarshan.
The base business of Sudarshan is also averaging only 14-15% pre-tax ROCE which is not great. It might be the 3rd largest pigment player globally but it doesn’t seem to have high bargaining power with the customers.
And current valuations are nose bleeding. More than 50 PE
A medicore base business, a large acqusition which is more likely to be tough than easy, the prospects of leverage clearly going up. And such high valuations. What am I missing ?